December 2015, Vol. 4, No. 6
Sample Size Calculation for Single-Arm Phase 2 Prostate Cancer Trials
Prostate cancer remains one of the major health issues for men worldwide and is the second leading cause of cancer-related death in males in the United States…
Related Articles
The Current Landscape in Melanoma Treatment
An Interview with Jeffrey Infante, MD, of Sarah Cannon Research InstituteThe COMBI-d and COMBI-v trials showed that treating BRAF V600 mutation–positive metastatic melanoma with the combination of dabrafenib plus trametinib resulted in a significant increase in overall survival and a 33% reduction in the risk of progression or death compared [ Read More ]
FDA Approves Opdivo to Treat Advanced Form of Kidney Cancer
On November 23, 2015, the FDA approved Opdivo (nivolumab) to treat patients with advanced (metastatic) renal cell carcinoma, a form of kidney cancer, who have received a certain type of prior therapy. “Opdivo provides an important therapy option for patients with renal cell carcinoma,” said Richard Pazdur, MD, Director of [ Read More ]